Accessibility Menu
Daiichi Sankyo, logo

Daiichi Sankyo,(OTC) DSNKY

Market Cap$32.17BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2011)+187%
5 Year-6%
1 Year-27%
1 Month+9%
$18.23
+3.11%
+0.55Today
Daiichi Sankyo, last closing stock price
MetricPriceDate
Last closeUSD 17.682026-07-29
Daiichi Sankyo, stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+3.63%USD 17.062026-07-22
1 month+8.93%USD 16.232026-06-29
3 month+7.74%USD 16.412026-04-30
Year to date-16.76%USD 21.242025-12-31
1 year-26.87%USD 24.182025-07-29
3 year-40.11%USD 29.522023-07-28
5 year-6.03%USD 18.812021-07-30
Since inception+186.73%USD 6.172011-11-14

Daiichi Sankyo, Financials at a Glance

Market Cap

$32.17BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

¥2.15T

Net Income (TTM)

¥263.01B

EPS (TTM)

$0.94

P/E Ratio

18.90

Dividend

$0.49

Beta (Volatility)

0.58 (Low)

Price

$18.23

Volume

265,080

Open

$17.34

Previous Close

$18.23

Daily Range

$17.34 - $18.24

52-Week Range

$14.98 - $27.50

Estimated Earnings Date

Jul 31, 2026

DSNKY News

Female scientist with pipette in lab

5 Most Valuable Pipeline Drugs in Development -- and the Stocks Poised to Profit

Keith SpeightsJun 12, 2019

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Daiichi Sankyo,

Daiichi Sankyo Company, Limited is a global pharmaceutical enterprise that encompasses the entire lifecycle of drug development, from pioneering research and development to manufacturing, importation, marketing, and worldwide distribution of its medicinal products. Established in 1899 and headquartered in Tokyo, Japan, the company offers a diverse portfolio of pharmaceutical products across various therapeutic areas.

Products and Services
  • Oncology treatments, including trastuzumab deruxtecan and gefitinib
  • Cardiovascular and metabolic health products like teneligliptin and edoxaban
  • Neurology and pain management solutions, including mirogabalin and lacosamide
Growth Outlook
  • Recent collaborations, such as with Guardant Health, enhance diagnostic capabilities
  • Expansion in oncology and cardiovascular markets drives future revenue potential
  • Focus on innovative drug development supports long-term growth strategies
Financial Highlights
  • Latest quarterly revenue of 600.42 billion JPY shows strong market performance
  • Net income for the quarter reached 43.21 billion JPY, reflecting profitability
  • Trailing twelve months (TTM) net profit margin stands at 12.24%, indicating operational efficiency
Daiichi Sankyo Company, Limited operates in the healthcare sector, focusing on drug manufacturing and development. The company has established a strong presence in various therapeutic areas, including oncology, cardiovascular health, neurology, and pain management. Its commitment to research and development is evident in its extensive product offerings and strategic collaborations, which position the company for future growth. Recent financial performance highlights a robust revenue stream, with the latest quarterly revenue reaching 600.42 billion JPY. The net income of 43.21 billion JPY for the same period underscores the company's ability to maintain profitability. Additionally, the TTM net profit margin of 12.24% reflects effective cost management and operational efficiency. Daiichi Sankyo's focus on innovative drug development and strategic partnerships is expected to drive growth in the coming years. The company's diverse portfolio and commitment to addressing unmet medical needs position it well within the competitive pharmaceutical landscape.
AI Generated • Jul 21, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

20,171

CEO

Hiroyuki Okuzawa

Website

www.daiichisankyo.co.jp

Headquarters

Tokyo, TY 103-8426, JP

DSNKY Financials

Key Financial Metrics (TTM)

Gross Margin

68.49%

Operating Margin

9.80%

Net Income Margin

12.24%

Return on Equity

15.74%

Return on Capital

11.14%

Return on Assets

6.49%

Earnings Yield

5.29%

Dividend Yield

2.78%

Payout Ratio

49.42%

Stock Overview

Market Cap

$32.17BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.82B

Volume

265.08K

Avg. Volume

315.82K

Financials (TTM)

Gross Profit

¥1.47T

Operating Income

¥210.05B

EBITDA

¥322.53B

Operating Cash Flow

¥83.77B

Capital Expenditure

-¥129.41B

Free Cash Flow

-¥45.64B

Cash & ST Invst.

¥451.76B

Total Debt

¥301.78B

Daiichi Sankyo, Performance Analysis

Daiichi Sankyo, annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31JPY 9,437,849,0681.5%
20242024-03-31JPY 11,090,991,16917.5%
20252025-03-31JPY 12,372,918,73811.6%
20262026-03-31JPY 14,088,629,81013.9%
Daiichi Sankyo, sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-06-30-8.5%
Q22025-09-307.4%
Q32025-12-3111.5%
Q42026-03-315.7%
Daiichi Sankyo, annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31JPY 0.4235.2%
20242024-03-31JPY 0.7272.5%
20252025-03-31JPY 1.0241.1%
20262026-03-31JPY 0.93-8.9%
Daiichi Sankyo, sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-06-30-0.8%
Q22025-09-30-45.9%
Q32025-12-3191.1%
Q42026-03-31-49.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

¥600.42B

+15.8%

Gross Profit

¥292.42B

-31.1%

Gross Margin

48.70%

N/A

Market Cap

$32.17BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.59M

N/A

Employees

20,171

N/A

Net Income

¥43.21B

-50.4%

EBITDA

-¥992.91M

-101.0%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

¥451.76B

-37.3%

Total Debt

¥301.78B

+197.8%

Accounts Receivable

¥744.36B

+20.2%

Inventory

¥695.38B

+35.0%

Long Term Debt

¥301.38B

+198.6%

Short Term Debt

¥405.75M

+1.7%

Return on Assets

6.49%

N/A

Return on Invested Capital

6.67%

N/A

Free Cash Flow

-¥3.57B

-110.0%

Operating Cash Flow

¥26.05B

-63.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
HLNCFHaleon plc
$5.03-0.40%
UCBJYUCB S.A.
$124.85-12.62%
LZAGFLonza Group AG
$687.76-2.46%
UCBJFUCB S.A.
$259.59-13.47%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$91.13+0.11%
NVDANvidia
$195.04+0.03%
MSFTMicrosoft
$451.10+0.16%
NOKNokia
$9.09+0.08%

Questions About DSNKY

What is the current price of Daiichi Sankyo,?

Daiichi Sankyo, is trading at $18.23 per share.

What is the 52-week range for Daiichi Sankyo,?

Over the past 52 weeks, Daiichi Sankyo, has traded between $14.98 and $27.50.

How much debt does Daiichi Sankyo, have?

As of the most recent reporting period, Daiichi Sankyo, reported total debt of ¥2.20B.

How much cash does Daiichi Sankyo, have on hand?

Daiichi Sankyo, reported ¥1.67B in cash and cash equivalents in its most recent financial results.

What is Daiichi Sankyo,’s dividend yield?

Daiichi Sankyo, currently has a dividend yield of 2.78%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services